| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
90,630,000 |
| Market
Cap: |
15.17(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$129.52 - $242.06 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 664 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile BeiGene is a commercial-stage biotechnology company focused on developing and commercializing molecularly-targeted and immuno-oncology cancer therapeutics. Co.'s clinical-stage drug candidates include: Zanubrutinib, which is a small molecule inhibitor of Bruton's tyrosine kinase for the treatment of mantle cell lymphoma in adult patients; Tislelizumab, which is a humanized monoclonal antibody against the immune checkpoint receptor programmed cell death protein 1; Pamiparib (BGB-290), which is for the treatment of various solid tumors; and Lifirafenib, which is an investigational small molecule inhibitor with RAF monomer and dimer inhibition activities.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
100,397 |
100,397 |
5,364,251 |
5,588,274 |
| Total Sell Value |
$15,909,372 |
$15,909,372 |
$1,039,781,980 |
$1,085,894,829 |
| Total People Sold |
2 |
2 |
8 |
9 |
| Total Sell Transactions |
6 |
6 |
20 |
54 |
| End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Peterson Amy C. |
CMO, Immuno-oncology |
• – – |
2018-11-12 |
4 |
OE |
$29.10 |
$351,150 |
D/D |
12,067 |
12,067 |
|
- |
|
| Peterson Amy C. |
CMO, Immuno-oncology |
• – – |
2018-11-09 |
4 |
AS |
$118.64 |
$1,593,163 |
D/D |
(13,222) |
0 |
|
- |
|
| Peterson Amy C. |
CMO, Immuno-oncology |
• – – |
2018-11-09 |
4 |
OE |
$29.10 |
$384,760 |
D/D |
13,222 |
13,222 |
|
- |
|
| Peterson Amy C. |
CMO, Immuno-oncology |
• – – |
2018-11-08 |
4 |
AS |
$122.86 |
$1,854,577 |
D/D |
(14,711) |
0 |
|
- |
|
| Peterson Amy C. |
CMO, Immuno-oncology |
• – – |
2018-11-08 |
4 |
OE |
$29.10 |
$428,090 |
D/D |
14,711 |
14,711 |
|
- |
|
| Huang Jane |
CMO, Hematology |
• – – |
2018-09-04 |
4 |
AS |
$174.60 |
$508,247 |
D/D |
(2,911) |
0 |
|
- |
|
| Glazer Donald W. |
Director |
– • – |
2018-08-30 |
4 |
S |
$179.00 |
$179,000 |
D/D |
(1,000) |
13,384 |
|
- |
|
| Glazer Donald W. |
Director |
– • – |
2018-08-29 |
4 |
S |
$179.00 |
$179,000 |
D/D |
(1,000) |
14,384 |
|
- |
|
| Peterson Amy C. |
CMO, Immuno-oncology |
• – – |
2018-08-23 |
4 |
AS |
$167.54 |
$975,666 |
D/D |
(5,769) |
0 |
|
- |
|
| Wang Xiaodong |
Director |
– • – |
2018-08-13 |
4 |
S |
$157.29 |
$547,591 |
D/D |
(3,449) |
0 |
|
- |
|
| Baker Julian |
Director |
– • • |
2018-08-02 |
4 |
B |
$108.00 |
$627,922,800 |
I/I |
5,814,100 |
5,250,491 |
2.25 |
- |
|
| Oyler John |
Chief Executive Officer |
• • • |
2018-07-16 |
4 |
S |
$164.12 |
$418,497 |
D/D |
(2,550) |
0 |
|
- |
|
| Peterson Amy C. |
CMO, Immuno-oncology |
• – – |
2018-06-26 |
4 |
A |
$0.00 |
$0 |
D/D |
44,564 |
269,566 |
|
- |
|
| Wang Xiaodong |
Director |
– • – |
2018-06-26 |
4 |
A |
$0.00 |
$0 |
D/D |
94,133 |
7,973,444 |
|
- |
|
| Oyler John |
Chief Executive Officer |
• • • |
2018-06-26 |
4 |
A |
$0.00 |
$0 |
D/D |
188,266 |
17,453,322 |
|
- |
|
| Huang Jane |
CMO, Hematology |
• – – |
2018-06-26 |
4 |
A |
$0.00 |
$0 |
D/D |
44,564 |
309,464 |
|
- |
|
| Liang Howard |
CFO & Chief Strategy Officer |
• – – |
2018-06-26 |
4 |
A |
$0.00 |
$0 |
D/D |
52,338 |
52,338 |
|
- |
|
| Wang Xiaodong |
Director |
– • – |
2018-06-08 |
4 |
GD |
$0.00 |
$0 |
D/D |
5,000,000 |
7,879,311 |
|
- |
|
| Baker Julian |
Director |
– • • |
2018-06-06 |
4 |
A |
$0.00 |
$0 |
I/I |
37,160 |
73,180,602 |
|
- |
|
| Malley Thomas |
Director |
– • – |
2018-06-06 |
4 |
A |
$0.00 |
$0 |
D/D |
9,290 |
9,290 |
|
- |
|
| Glazer Donald W. |
Director |
– • – |
2018-06-06 |
4 |
A |
$0.00 |
$0 |
D/D |
9,290 |
4,336,932 |
|
- |
|
| Chen Timothy Yung-Cheng |
Director |
– • – |
2018-06-06 |
4 |
A |
$0.00 |
$0 |
D/D |
9,290 |
9,290 |
|
- |
|
| Yi Qingqing |
Director |
– • – |
2018-06-06 |
4 |
A |
$0.00 |
$0 |
D/D |
9,290 |
9,290 |
|
- |
|
| Wu Xiaobin |
President & GM China |
• – – |
2018-04-30 |
4 |
A |
$0.00 |
$0 |
D/D |
1,149,899 |
1,149,899 |
|
- |
|
| Oyler John |
Chief Executive Officer |
• • • |
2018-04-30 |
4 |
A |
$0.00 |
$0 |
D/D |
574,938 |
17,265,056 |
|
- |
|
527 Records found
|
|
Page 17 of 22 |
|
|
6.93 (3.98%) 
